A new semi-automated instrument to improve the fine needle aspiration procedure during breast lesion cell sampling

Wiksell, Hans; Ekstrand, Vilhelm; Wadström, C; Auer, Gert

doi:10.1016/j.ejmp.2008.09.001

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An average of ≈2 mg of material or ≈1000 cells (range 100-5000) can be obtained from a single needle pass. Because the materials can be of such low cellularity, the rate of nondiagnostic specimens can be as high as 30%, [21,22] even with expert sampling and processing. To determine whether i2SCAN could be used for multiplexed analyses of single cells, we first processed cell lines whose marker presence is established and can be independently validated by flow cytometry.…”

Section: Multiplexed Analysis In Single-cell Suspensionsmentioning

confidence: 99%

Integrated Analytical System for Clinical Single‐Cell Analysis

et al. 2022

View full text Add to dashboard Cite

High‐dimensional analyses of cancers can potentially be used to better define cancer subtypes, analyze the complex tumor microenvironment, and perform cancer cell pathway analyses for drug trials. Unfortunately, integrated systems that allow such analyses in serial fine needle aspirates within a day or at point‐of‐care currently do not exist. To achieve this, an integrated immunofluorescence single‐cell analyzer (i2SCAN) for deep profiling of directly harvested cells is developed. By combining a novel cellular imaging system, highly cyclable bioorthogonal FAST antibody panels, and integrated computational analysis, it is shown that same‐day analysis is possible in thousands of harvested cells. It is demonstrated that the i2SCAN approach allows comprehensive analysis of breast cancer samples obtained by fine needle aspiration or core tissues. The method is a rapid, robust, and low‐cost solution to high‐dimensional analysis of scant clinical specimens.

show abstract

Section: Multiplexed Analysis In Single-cell Suspensionsmentioning

confidence: 99%